Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
American Eagle Outfitters is trading at bargain multiples despite Aerie and OFFLINE driving mid-20% comparable sales growth. Fundamentals - low leverage, meaningful free cash flow, and an EV/EBITDA of ~4.6 - support a long trade into the next two earnings cycles. Entry at $17.75, target $25.00, stop $14.50 for a long-term (180 trading days) swing.
Gold is trading around $4,029, down about 1.17% on the day and roughly 25.4% below six-month highs, as investors weigh a possible Fed rate move against ongoing structural demand from central banks. Technical indicators on daily and weekly charts read Strong Sell, yet heavy central bank purchases and oversold weekly momentum indicators leave scope f…
Atour is trading at a sensible earnings multiple with a $4.6B market cap, accelerating room additions and recurring dividend policy. Ahead of Q2 2026 results, the setup favors a mid-term long: buy near $34.00, target $42.00 on a successful print and guidance lift, stop at $30.50 to protect against a macro or execution shock.
India's industrial production accelerated to a 7.3% year-on-year increase in June, driven primarily by stronger manufacturing activity and higher electricity generation. The monthly figures included a methodological switch in the calculation of factory output and showed a notable acceleration in quarterly industrial growth for April-June.
Synopsys sits at the intersection of chip design software and physics-based simulation. Recent industry moves - notably NVIDIA's agent toolkits and Synopsys' broader product set following the Ansys deal - create a durable addressable market expansion. The company trades at a premium multiple today but generates strong free cash flow and has structu…
Trevi Therapeutics, a clinical-stage biopharmaceutical company developing Haduvio™ for chronic cough related to idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough, announced its management's participation in key August biotech conferences to discuss clinical progress and company strategy.
Harvard Bioscience, Inc. has scheduled the announcement of its second quarter 2026 financial results for August 11, 2026, before market opening. The company will hold a conference call at 8:00 AM ET to discuss the results, providing analysts and investors with detailed insights into its performance.
Plus Therapeutics, a clinical-stage healthcare company focused on CNS cancers, announced upcoming presentations of its ReSPECT-LM clinical program and CNSide diagnostic platform at the 2026 SNO/ASCO CNS Metastases Conference. The company will also host a sponsored symposium on leptomeningeal metastases management. Additionally, Plus Therapeutics wi…
Hubbell Incorporated (NYSE: HUBB) delivered solid Q2 2026 performance, reporting a 15% increase in net sales and a 12% rise in adjusted diluted EPS to $5.52. Organic sales growth was driven by strong demand in utility solutions and electrical solutions segments, fueled by megatrends like grid modernization and datacenter investments. Adjusted opera…
Venus Concept Inc., a leader in medical aesthetic technology, has obtained exclusive rights to distribute HIRONIC's Doublo 2.0 device in the United States and Canada. The new device, which incorporates Cold Plasma and RF microneedling technologies, has received FDA 510(k) clearance and will be launched in the US in the second half of 2026. Venus Co…
Palvella Therapeutics, a clinical-stage biopharmaceutical company focused on novel therapies for rare skin diseases and vascular malformations, will announce its Q2 2026 financial results before market open on August 4, 2026, followed by a corporate update conference call. The company is developing therapies based on its QTORIN platform, with lead …
3D Systems played a pivotal role in enabling the Defense Health Agency and Walter Reed 3D Medical Applications Center to receive FDA premarket clearance for the Titanium Cranial Plate System, the first FDA-cleared implant granted to a point-of-care institution. This milestone exemplifies the advancement of additive manufacturing in clinical environ…
Dyne Therapeutics announces FDA clearance of its Investigational New Drug application for DYNE-302, advancing its third clinical program leveraging the FORCE platform to treat facioscapulohumeral muscular dystrophy (FSHD), a rare progressive neuromuscular disorder with no approved therapies. The Phase 1 trial will assess safety, tolerability, pharm…
ZenaTech has commenced flight testing of its Interceptor P-1, a low-cost, autonomous counter-UAS drone designed to physically intercept hostile drones. This marks a significant milestone in expanding its defense portfolio with affordable counter-drone solutions integrating AI and autonomous swarm operations. The company aims to address growing glob…
Riot Platforms, Inc., a leader in large-scale data centers and bitcoin mining, announced its Q2 2026 earnings call set for August 5, 2026. The company focuses on developing digital infrastructure and mining operations across Texas and Kentucky, with engineering facilities in Denver and Houston. The press release reiterates forward-looking statement…
Nasus Pharma, a clinical-stage biopharmaceutical company developing innovative intranasal therapies, announced the appointment of pharmaceutical industry veteran Brendan P. O'Grady as CEO. O'Grady will lead the next phase of growth with an emphasis on unlocking the commercial potential of NS002, an intranasal epinephrine treatment targeting a $2 bi…
PMGC Holdings Inc., through its subsidiary A&B Aerospace, has entered a long-term manufacturing agreement with Precision Aerospace & Defense Group to supply precision-machined aerospace and defense components. Additionally, PMGC made a $500,000 strategic equity investment in PAD Group, further aligning their partnership. This collaboration position…
Kiniksa Pharmaceuticals reported robust second quarter 2026 financial results highlighted by 55% year-over-year net product revenue growth for ARCALYST®, reaching $243.6 million in Q2. The company raised its full-year 2026 ARCALYST revenue guidance to $980-$995 million. Clinical progress continues with promising Phase 2 data for KPL-387 supporting …
Advanced Micro Devices sits in the middle of two powerful narratives: accelerating adoption in heterogeneous, chiplet-driven inference infrastructure and a secular push to 'ARM-ify' server compute that could compress margins and pricing power. The recent price drop offers an actionable long entry at $495.07 with a $590 target over 180 trading days,…
According to KAYAK, a travel search engine owned by Booking Holdings, French families traveling with children under two in summer 2026 prefer shorter flights mainly to Mediterranean destinations within about three hours of France. Popular locations include Spain, Portugal, Morocco, and Tunisia. The travel pattern reflects the need to minimize fligh…
Digital Currency X Technology Inc. has announced comprehensive upgrades to its DexTrader on-chain data platform, enhancing data architecture, omnichain capabilities, and user services. The company aims to target the digital asset information niche for token-based derivatives, yield instruments, and collateralized assets, positioning DexTrader as a …
Corning Inc. tumbled 11.4% in pre-market trading after releasing its Q2 2026 results ahead of the open. Investors reacted to tempered forward guidance and signals that capital spending from major wireless carriers may slow, weighing on expectations for the company’s Optical Communications segment. The move exceeded options-implied volatility and co…
PayPal pushed forward with an aggressive turnaround program after reporting a quarter that outperformed expectations, increasing its 2026 profit projection and detailing multi-year cost, organizational and technology initiatives. The moves come as the company faces a $60.50-per-share takeover bid that its board has deemed insufficient and as compet…
Altimmune Inc. saw its stock rise 18% after reporting topline results from the RECLAIM Phase 2 trial of pemvidutide for alcohol use disorder. The study met its primary endpoint, showing a statistically significant reduction in heavy drinking days versus placebo, and achieved secondary endpoints recognized by the FDA as registrational. The 2.4 mg do…
Lifecore Biomedical announced three new customer agreements, including a late-stage regenerative medicine program and two early-stage projects supporting medical technology development. These agreements diversify Lifecore's pipeline and are expected to contribute to revenue starting in 2028, reinforcing its position as a key player in the CDMO mark…
